Ozempic versus Mounjaro. GLP-1 alone versus GLP-1 plus GIP. The clinical trial data, the dosing differences, and a direct answer to which produces more weight loss.
A GLP-1 receptor agonist approved for both type 2 diabetes (Ozempic, up to 1 mg/week) and weight management (Wegovy, up to 2.4 mg/week). The first GLP-1 to achieve blockbuster status for weight loss. Weekly injection, 7-day half-life, and a well-established tolerability profile after years of widespread use. Average weight loss in trials: approximately 15% of body weight.
A dual GLP-1 and GIP receptor agonist approved for T2D (Mounjaro) and weight management (Zepbound). The addition of GIP receptor activation adds a complementary mechanism that enhances fat metabolism and appears to reduce nausea. Consistently outperforms Semaglutide in head-to-head and trial data for both weight loss (~20–22%) and HbA1c reduction.
Clinical trial results
~15%
Semaglutide avg. weight loss
STEP-1 trial (2.4 mg/week)
~20–22%
Tirzepatide avg. weight loss
SURMOUNT-1 trial (15 mg/week)
Tirzepatide
Head-to-head advantage
SURPASS-6 trial, direct comparison
| Semaglutide | Tirzepatide | |
|---|---|---|
| Class | GLP-1 receptor agonist | Dual GLP-1 / GIP receptor agonist |
| Brand names | Ozempic (T2D), Wegovy (weight loss) | Mounjaro (T2D), Zepbound (weight loss) |
| Mechanism | Activates GLP-1 receptors → reduced appetite, slower gastric emptying, insulin release | Activates both GLP-1 and GIP receptors — dual incretin mechanism |
| Starting dose | 0.25 mg/week | 2.5 mg/week |
| Maximum dose | 2.4 mg/week (Wegovy) / 1.0 mg/week (Ozempic) | 15 mg/week |
| Avg. weight loss | ~15% body weight (STEP trials) | ~20–22% body weight (SURMOUNT trials) |
| HbA1c reduction | ~1.5–1.8% | ~2.0–2.3% |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| FDA approved | Yes — weight (2021), T2D (2017) | Yes — weight (2023), T2D (2022) |
| Titration | 4-week intervals (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) | 4-week intervals (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg) |
| Half-life | ~7 days | ~5 days |
| Patent expiry | US: ~2032 | US: ~2036 |
The GIP receptor (glucose-dependent insulinotropic polypeptide) plays a distinct but complementary role to GLP-1. GIP primarily acts on fat tissue — it suppresses lipolysis at low doses and enhances it at higher doses, and it has direct effects on the brain's reward circuitry that appear to reduce food intake through a separate pathway to GLP-1. Activating both simultaneously seems to produce additive — possibly synergistic — appetite suppression.
GIP also has a counterintuitive anti-nausea effect. This may partly explain why Tirzepatide, despite producing greater weight loss, appears to cause similar or slightly lower rates of GI side effects compared to equivalent doses of Semaglutide.
Semaglutide has a longer track record. It has been used at scale since 2017 (diabetes) and 2021 (weight management), with a substantial body of real-world safety data now available. For people who respond well to GLP-1 monotherapy, or who want a more conservative starting point, Semaglutide remains a strong option. It is also likely to become more accessible as generic versions enter the market from around 2026.
Both compounds use a slow titration to allow the body to adapt and minimise GI side effects. The doses should not be rushed — titrating too quickly is the main driver of intolerable nausea.
Semaglutide titration (Wegovy)
Tirzepatide titration (Zepbound)
On the numbers, Tirzepatide wins on weight loss and blood sugar control. The dual mechanism is demonstrably more effective than GLP-1 alone, and the side effect profile is comparable. If maximum weight loss is the goal and both are accessible to you, Tirzepatide is the stronger choice. That said, Semaglutide remains highly effective — a 15% reduction in body weight is substantial — and its longer track record provides additional reassurance for people cautious about newer therapies.
Semaglutide activates only the GLP-1 receptor — the pathway that reduces appetite, slows gastric emptying, and stimulates insulin release. Tirzepatide activates both GLP-1 and GIP receptors. GIP is a second incretin hormone that has complementary effects on fat metabolism and insulin sensitivity. The dual mechanism gives Tirzepatide a measurable advantage in average weight loss and blood sugar control.
Tirzepatide produces greater average weight loss. In the SURMOUNT-1 trial, participants on the highest Tirzepatide dose (15 mg) lost an average of 22.5% of body weight. Comparable Semaglutide trials (STEP-1, Wegovy 2.4 mg) showed approximately 14.9% weight loss. Head-to-head data from the SURPASS-6 trial also showed Tirzepatide outperforming Semaglutide on weight reduction.
The side effect profiles are similar — nausea, vomiting, diarrhoea, and constipation are the most common with both. These are generally worst during dose escalation and improve after 4–8 weeks. Some data suggests Tirzepatide may have a slightly lower rate of nausea than Semaglutide at comparable doses, potentially because GIP receptor activation has anti-nausea properties.
Both are brand names for the same molecule: Semaglutide. Ozempic is approved for type 2 diabetes management (maximum dose 1.0 mg/week). Wegovy is approved specifically for weight management (maximum dose 2.4 mg/week). The titration schedule and maximum dose differ between them.
Both are brand names for Tirzepatide. Mounjaro is the T2D indication; Zepbound is the obesity/weight management indication. The doses and titration schedules are identical — the difference is the approved indication and often the price.
Tirzepatide produces greater HbA1c reductions than Semaglutide. In the SURPASS trial programme, Tirzepatide reduced HbA1c by approximately 2.0–2.3 percentage points versus 1.5–1.8% for Semaglutide. For people managing type 2 diabetes, this difference is clinically meaningful.
Both are dosed weekly by subcutaneous injection and follow a gradual titration. Semaglutide starts at 0.25 mg/week and increases every 4 weeks up to a maximum of 2.4 mg (Wegovy) or 1.0 mg (Ozempic). Tirzepatide starts at 2.5 mg/week and titrates up every 4 weeks to a maximum of 15 mg. The dose numbers look very different but are not directly comparable — they use different dosing scales.
Log weekly injections, track dose escalation, and monitor your body metrics — weight, body fat, and waist — over the full course of your protocol.
Start Free Trial